Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Elderly patients undergoing transurethral resection face a higher risk of developing postoperative cognitive dysfunction POCD and delirium, which can lead to longer hospital stays, more complications, and a lower quality of life. This observational study aims to find perioperative factors linked to POCD and delirium in patients aged 65 and older and to create a risk prediction model to help identify those at greater risk. Cognitive function and delirium are measured using the Montreal Cognitive Assessment MoCA and the Confusion Assessment Method CAM. Participants aged 65 years and above scheduled for transurethral resection will be followed before, during, and after surgery. Baseline information such as demographics, frailty, comorbidities, and cognitive status will be collected. During surgery, details about anesthesia, procedure length, and intraoperative events will be recorded. After surgery, cognitive function and delirium will be assessed on postoperative days 1, 2, and 3 using MoCA and CAM to monitor changes. Throughout the study, participants will undergo repeated cognitive and delirium assessments to identify factors independently associated with POCD and delirium. The research team will develop and evaluate a predictive risk model using statistical methods. The study may help clinicians recognize vulnerable patients earlier and support more personalized perioperative care. The total study duration spans from baseline assessment before surgery through postoperative day 3, with final analysis expected by November 2026.
Actively Recruiting
Researchers are investigating the possible link between hemorrhoids and coughing by studying patients who visit a general surgery outpatient clinic with symptoms such as bleeding, pain, itching, fecal leakage, prolapse, and mucus discharge. The study aims to determine if coughing is a contributing factor to hemorrhoids by assessing cough symptoms, including their presence, duration, and frequency, in patients diagnosed with hemorrhoidal disease. This prospective, observational study will gather detailed information on cough severity, comorbid chest diseases, and smoking history among these patients. Patients diagnosed with hemorrhoidal disease will be examined and graded based on mucosal prolapse according to the Goligher classification. Evaluations will include physical exams, height and weight measurements, and questionnaires such as the Leicester Cough Questionnaire and the Cough Visual Analog Scale. Cough duration will be categorized as acute or chronic, and additional data will be collected on chest diseases and smoking status. Patients with cough will be referred for further chest disease evaluation. Participants will provide demographic and clinical information, including cough and hemorrhoid symptoms, comorbidities, and lifestyle factors. The study will measure the relationship between hemorrhoid severity and cough characteristics, along with chest disease presence and smoking history. Data will be collected between March and June 2025, and the primary outcome will focus on cough severity as measured by the Leicester Cough Questionnaire.
Actively Recruiting
Healthy Volunteer
Researchers are studying the effects of Reiki and self-acupressure on functionality and quality of life in people with multiple sclerosis. Reiki is a complementary energy practice involving gentle hand placement on key body areas to promote energy flow, which has been shown to help with symptoms like pain, depression, insomnia, and fatigue. This randomized controlled trial aims to compare Reiki, self-acupressure, and no intervention groups to understand their impact on multiple sclerosis symptoms and daily functioning. Participants will be divided into three groups one receiving Reiki treatments, one practicing self-acupressure, and a control group with no intervention. Reiki treatments involve the practitioner holding their hands on various body points for 3-5 minutes, possibly extended to 10-20 minutes for problematic areas, with sessions lasting 30-90 minutes. Self-acupressure is a self-administered technique, while the control group does not receive any specific treatment. During the study, participants will be assessed over four weeks using tools measuring quality of life and functional abilities related to multiple sclerosis. Researchers will monitor changes in symptoms and overall well-being. The trial includes safety monitoring and excludes those with certain health conditions or recent treatments that could affect results. The total participation period is at least four weeks, during which participants will be observed and evaluated regularly.
Actively Recruiting
Researchers are studying how two types of electrical stimulation therapies, interferential current therapy and conventional transcutaneous electrical nerve stimulation TENS, compare to a placebo in managing pain and comfort after cesarean section. This trial includes 54 first-time mothers aged 18 to 40 years and aims to evaluate immediate and short-term effects on pain and postpartum comfort. The study is a prospective, randomized, placebo-controlled clinical trial conducted in a hospital setting. Participants will be randomly assigned to one of three groups conventional TENS, interferential current therapy, or placebo stimulation. Each session lasts 30 minutes and is performed with participants lying down with electrodes placed around the cesarean incision. The active therapies apply electrical currents at specified frequencies and intensities adjusted for comfort, while the placebo group receives the device setup without electrical current. During the study, pain intensity at rest and during in-bed activities will be measured before treatment, immediately after, and at 1 and 2 hours post-intervention. Postpartum comfort, treatment satisfaction, anxiety, and depression levels will also be evaluated using questionnaires and scales. All assessments are done by an assessor who does not know the group assignments, ensuring unbiased results. The total participation timeline covers these assessments within a few hours around the intervention.
Actively Recruiting
Researchers are evaluating the use of a pain diary to assess early postoperative pain in patients undergoing elective laparoscopic cholecystectomy. This randomized controlled trial compares a pain diary group to a control group receiving routine pain assessment using the Visual Analog Scale VAS. The study aims to improve patient involvement in pain evaluation without adding new pain medications. Patients are randomly assigned to one of two groups. The intervention group uses a patient-completed pain diary introduced before surgery to record pain intensity at rest and during movement at specific times after surgery. The control group receives standard care with pain assessed by nurses and researchers using VAS at the same postoperative times. Both groups follow a pain management protocol tailored for laparoscopic cholecystectomy and are cared for in separate hospital rooms to prevent mix-up. Participants will have their pain intensity measured at nine time points within the first 48 hours after surgery 2, 4, 6, 12, 16, 20, 24, 32, and 48 hours. Additional pain assessments are done during this period. The study includes evaluations of pain intensity using standardized tools, and outcomes compare the pain diary with routine assessment methods. Safety and study adherence will be monitored throughout the hospital stay, which is expected to be at least 24 hours after surgery.
Actively Recruiting
Researchers are evaluating the effect of remote ischemic preconditioning RIPC on protecting the heart muscle during coronary artery bypass graft CABG surgery in patients with type 2 diabetes mellitus. This clinical trial addresses the concern of heart muscle injury during CABG, which is especially significant in high-risk diabetic patients. RIPC is a low-cost, non-invasive method that may help reduce heart damage by increasing tolerance to reduced blood flow through brief, repeated cycles of limb blood flow restriction. Participants will be randomly assigned to one of two groups one group will receive RIPC before the surgery, which involves inflating a blood pressure cuff on the upper arm to 200 mmHg for 5 minutes followed by 5 minutes of deflation, repeated five times before the chest is opened. The other group will receive standard care without RIPC. This procedure is done under general anesthesia and is designed to keep participants unaware of their group assignment. During the study, researchers will monitor heart injury by measuring high-sensitivity troponin T levels at 24, 48, and 72 hours after surgery. They will also assess other outcomes such as acute kidney injury within 72 hours, the maximum dose of heart support medications used during the first 72 hours, and the length of stay in the intensive care unit and hospital up to 60 days. Participants will be closely observed through these assessments to understand the potential heart-protective role of RIPC in diabetic patients undergoing cardiac surgery.
Actively Recruiting
Healthy Volunteer
Preeclampsia is a complex pregnancy disorder marked by new high blood pressure after 20 weeks of pregnancy, along with symptoms like protein in the urine and organ complications. It is caused by poor placental blood flow and widespread blood vessel dysfunction, which can affect many organs including the eyes. This study aims to understand how preeclampsia affects the tiny blood vessels in the retina and choroid by using advanced eye imaging techniques. The study compares three groups pregnant women with preeclampsia diagnosed after 20 weeks, healthy pregnant women matched by age and pregnancy stage, and healthy non-pregnant women. All participants will undergo noninvasive eye exams using Optical Coherence Tomography OCT and Optical Coherence Tomography Angiography OCTA, which provide detailed images of retinal and choroidal blood flow and structure without discomfort. These scans will measure retinal vessel density, the size of the foveal avascular zone, and choriocapillaris flow deficits to detect microvascular changes. Participants will have outpatient imaging visits where these eye scans are performed quickly and painlessly. Researchers will analyze these images to identify patterns of microvascular damage linked to preeclampsia. The main outcomes measured include retinal vessel density and the foveal avascular zone area, with additional assessments of choriocapillaris flow, peripapillary vessel density, and retinal thickness. The study expects to run through about one year of participant follow-up to gather comprehensive data on these vascular changes.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether Alpha-1 Antitrypsin Deficiency AATD, a genetic condition that reduces a protective protein in the lungs, is more common in people who experience shortness of breath and show airway obstruction on breathing tests. This condition can lead to lung diseases like emphysema, especially in smokers. The study aims to better detect AATD in patients with breathing difficulties to improve diagnosis and treatment options. This is a prospective, case-control study involving patients visiting a pulmonary outpatient clinic for shortness of breath who undergo routine spirometry. Participants are divided into two groups based on lung function results those with airway obstruction and those without. Blood samples are collected to measure AAT protein levels and test for common genetic mutations linked to AATD. Laboratory staff analyzing these samples will not know the participants group assignments. Participants will have their breathing assessed by spirometry and their symptom severity recorded using a standardized scale. Smoking history is collected as well. Blood samples for AAT levels come from routine blood draws, while genetic testing uses a finger-prick sample. Data will be carefully recorded and analyzed to explore the relationship between AATD, airway obstruction, and symptoms. The study continues until early 2026, with results expected to help identify undiagnosed cases and guide future care.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.
1-10 of 11
1